Matt Kapusta, uniQure CEO

UniQure un­veils mixed Hunt­ing­ton's gene ther­a­py da­ta, shares tank

UniQure shared up­dat­ed da­ta from a Phase I/II study that showed a clin­i­cal ben­e­fit in a small group of pa­tients with Hunt­ing­ton’s dis­ease who re­ceived its gene ther­a­py, but con­flict­ing da­ta about the mu­tant Hunt­ingtin pro­tein sent shares $QURE down by about 40% on Wednes­day morn­ing.

The Dutch biotech on Wednes­day re­vealed new da­ta from the place­bo-con­trolled Phase I/II study with 26 pa­tients. Six­teen pa­tients were giv­en a low or high dose of AMT-130, with 10 pa­tients in the con­trol group.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.